ReviewTherapeutic advances in medical oncology2017
Recent developments in the treatment of metastatic colorectal cancer.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.The oncologist · 2023Pooled it
- Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review.PharmacoEconomics · 2020Pooled it
- Pooled it
- Kinetic Profiling ofJCO precision oncology · 2024Trial
- Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.International journal of clinical oncology · 2021Trial
- Dimethyl Fumarate Enhances Venetoclax-Induced Cell Death by Inhibiting Mitochondrial Respiration and Cell Cycle Control in Colorectal Cancer.Life (Basel, Switzerland) · 2026Article
- From mono- to multi-cellularFrontiers in cell and developmental biology · 2026Review
- Ubiquitination-related Gene UBTD1 Mediates Poor Prognosis of Colorectal Cancer and Affects Colorectal Cancer Cell Proliferation and Ferroptosis.Recent patents on anti-cancer drug discovery · 2026Article
- Anticancer Effects ofReports of biochemistry & molecular biology · 2024Article
- Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments.Cancer metastasis reviews · 2024Review
- Circular RNA hsa_circ_0005939 Regulates UHRF1BP1L Expression by Targeting miR-4693-3p to Promote Colorectal Cancer Progression.Protein and peptide letters · 2024Article
- Comprehension of rectosigmoid junction cancer molecular features by comparison to the rectum or sigmoid colon cancer.Journal of gastrointestinal oncology · 2023Article
- Tenglong Buzhong granules inhibits the growth of SW620 human colon cancer.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Potentials of long non-coding RNAs as biomarkers of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Article
- Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion.Molecular biotechnology · 2022Article
- LncRNA ARST is a Novel Prognostic and Diagnostic Biomarker for Colorectal Cancer.Cancer management and research · 2022Article
- Review of various NAMPT inhibitors for the treatment of cancer.Frontiers in pharmacology · 2022Review
- Downregulation of hsa-miR-135b-5p Inhibits Cell Proliferation, Migration, and Invasion in Colon Adenocarcinoma.Genetics research · 2022Article
- Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data.Cancers · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the past decade there have been significant advances in the molecular characterization of colorectal cancer (CRC) that are driving treatment decisions. Expanded
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.